Indolent Non-Hodgkin Lymphoma
Oncology·MeSH: Lymphoma, Large B-Cell, Diffuse
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Preclinical(1)
| Drug | Company |
|---|---|
| zandelisib | Lite Strategy, Inc. (LITS) |
Frequently asked questions
How many drugs are in development for Indolent Non-Hodgkin Lymphoma?
BioSniper tracks 1 drug in development for Indolent Non-Hodgkin Lymphoma across 1 company.
How many clinical trials target Indolent Non-Hodgkin Lymphoma?
There are 2 clinical trials targeting Indolent Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Indolent Non-Hodgkin Lymphoma?
The estimated prevalence of Indolent Non-Hodgkin Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Indolent Non-Hodgkin Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis